materially affect our business, financial condition or future results.
ITEM 5.
OTHER INFORMATION
(c)
On
October 25, 2024
,
Joseph F. Fitzgerald
, our
Executive Vice President and Group President, Cardiology
, terminated a trading plan that was originally entered into on May 23, 2024 and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The plan covered the sale of up to
553,370
shares of our common stock, including up to
492,532
shares to be acquired upon exercise of stock options. Transactions under the plan were based upon pre-established dates and stock price thresholds.
On
February 27, 2025
,
Mr. Fitzgerald
entered into a new trading plan
intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Mr. Fitzgerald’s plan covers the sale of
306,372
shares of our common stock to be acquired upon exercise of stock options. Transactions under Mr. Fitzgerald’s plan are based upon pre-established dates and stock price thresholds and will only occur upon the expiration of the applicable mandatory cooling-off period. Mr. Fitzgerald’s plan will terminate on the earlier of
December 31, 2025
, or the date all shares subject to the plan have been sold.
ITEM 6. EXHIBITS
(* documents filed or furnished with this report; # compensatory plans or arrangements)
50
Table of Contents
51
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on May 1, 2025.
52